Balenciaga Giant City Charcoal Grey

This release contains certain forward looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward looking statements. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to Balenciaga City Silver Stud

Balenciaga Giant City Charcoal Grey

Balenciaga Giant City Charcoal Grey

Any forward looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward looking statements, whether as a result of new information, future events or otherwise.

Balenciaga Giant City Charcoal Grey

´╗┐Micromet to Host an Investor Meeting and Ring the Closing Bell of the NASDAQ Stock Exchange on April 24 2009 in New York

Balenciaga Giant City Charcoal Grey

Balenciaga Giant City Charcoal Grey

IDM Pharma, Inc. (IDMI) Receives The Nasdaq Stock Market New York Shareholder Equity Notification Amylin Pharmaceuticals, Inc. (AMLN) Board Battle Heats Up with Proxy Filing

Related NewsMicromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients BioPharm Executive Biogenerics: The Time Has Come

Micromet, Inc. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other Bottega Veneta Mini Roma Bag Price

Balenciaga Giant City Charcoal Grey

disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non Hodgkin's lymphoma. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Guess Clutch Bags Uk

Balenciaga Giant City Charcoal Grey

Balenciaga Giant City Charcoal Grey

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203 New Fund Mass Medical Angels to Back Life Sciences Firms

Balenciaga Giant City Charcoal Grey

Balenciaga Giant City Charcoal Grey

CONTACT: US Media: Andrea tenBroek, or Chris Stamm, +1 781 684 0770,

Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

be uncertain and forward looking. Factors that may cause actual results to differ materially from any future results expressed Balenciaga Giant City Charcoal Grey or implied by any forward looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10 K for the fiscal year ended December 31, 2008, filed with the SEC on March 16, 2009, as well as other filings by the company with the SEC.

Balenciaga Giant City Charcoal Grey

New Balance 996 Revlite
Guess Zip Around Wallet

Balenciaga Mini City Metallic Silver

Bottega Veneta Purses Sale

Guess Sling Bag For Men

Guess Cross Body Bags Uk

Balenciaga Tote Canvas

New Balance 574 Black Leather
New Balance 996 Dark Green
New Balance Classic 1300 Made In Usa
Guess Crossbody Black

Balenciaga City Classic Bag

Bottega Veneta Wallet Womens

New Balance 574 Trainers Red
Balenciaga Wallet Uk

Home / Balenciaga Giant City Charcoal Grey